Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 6, 2025
In the News
Louis Lehot Comments on Crypto Company IPO – 'Definitely a home run'
Foley & Lardner LLP partner Louis Lehot commented on the initial public offering of stablecoin issuer Circle in the Law360 article, "Circle's Smash IPO Could Pave Way For More Crypto Listings."
June 5, 2025
In the News
Michael Bennett and Zack Flagel Explore Pro Tennis Antitrust Battle
Foley & Lardner LLP attorneys Michael Bennett and Zack Flagel assess the antitrust litigation embroiling professional tennis in their LawInSport article, "Break(ing) Point? The Antitrust Battle that Could Transform Professional Tennis."